Terry-Ann  Burrell net worth and biography

Terry-Ann Burrell Biography and Net Worth

Terry-Ann Burrell has served as our Chief Financial Officer since August 2019 and as our Chief Financial Officer and Treasurer since September 2019. From May 2008 to August 2019, Ms. Burrell worked at J.P. Morgan Securities LLC, where she most recently served as Managing Director. Ms. Burrell was responsible for deal execution across both mergers and acquisitions and capital markets. In her role, she advised biotechnology and pharmaceutical companies on strategic considerations, including mergers and acquisitions, initial public and secondary offerings and valuation analysis. Ms. Burrell currently serves on the board of directors of Recursion Pharma, a biotherapeutics company. Ms. Burrell holds a bachelor’s degree from Harvard College and an MBA from New York University’s Leonard N. Stern School of Business. Provided by Tagnifi.

What is Terry-Ann Burrell's net worth?

The estimated net worth of Terry-Ann Burrell is at least $1.45 million as of July 13th, 2023. Ms. Burrell owns 54,847 shares of Beam Therapeutics stock worth more than $1,447,961 as of December 10th. This net worth estimate does not reflect any other investments that Ms. Burrell may own. Additionally, Ms. Burrell receives a salary of $711,150.00 as CFO at Beam Therapeutics. Learn More about Terry-Ann Burrell's net worth.

How old is Terry-Ann Burrell?

Ms. Burrell is currently 46 years old. There are 2 older executives and no younger executives at Beam Therapeutics. The oldest executive at Beam Therapeutics is Dr. Giuseppe Ciaramella Ph.D., President, who is 54 years old. Learn More on Terry-Ann Burrell's age.

What is Terry-Ann Burrell's salary?

As the CFO of Beam Therapeutics Inc., Ms. Burrell earns $711,150.00 per year. There are 2 executives that earn more than Ms. Burrell. The highest earning executive at Beam Therapeutics is Mr. John M. Evans M.B.A., CEO & Director, who commands a salary of $1,110,000.00 per year. Learn More on Terry-Ann Burrell's salary.

How do I contact Terry-Ann Burrell?

The corporate mailing address for Ms. Burrell and other Beam Therapeutics executives is 26 LANDSDOWNE STREET, CAMBRIDGE MA, 02139. Beam Therapeutics can also be reached via phone at 857-327-8775 and via email at [email protected]. Learn More on Terry-Ann Burrell's contact information.

Has Terry-Ann Burrell been buying or selling shares of Beam Therapeutics?

Terry-Ann Burrell has not been actively trading shares of Beam Therapeutics during the last quarter. Most recently, Terry-Ann Burrell sold 2,454 shares of the business's stock in a transaction on Monday, April 3rd. The shares were sold at an average price of $30.31, for a transaction totalling $74,380.74. Following the completion of the sale, the chief financial officer now directly owns 49,303 shares of the company's stock, valued at $1,494,373.93. Learn More on Terry-Ann Burrell's trading history.

Who are Beam Therapeutics' active insiders?

Beam Therapeutics' insider roster includes Terry-Ann Burrell (CFO), Giuseppe Ciaramella (Insider), Graham Cooper (Director), John Evans (CEO), and John Evans (CEO). Learn More on Beam Therapeutics' active insiders.

Are insiders buying or selling shares of Beam Therapeutics?

In the last twelve months, insiders at the sold shares 12 times. They sold a total of 284,412 shares worth more than $10,417,585.03. The most recent insider tranaction occured on October, 30th when insider Amy Simon sold 3,448 shares worth more than $64,477.60. Insiders at Beam Therapeutics own 4.4% of the company. Learn More about insider trades at Beam Therapeutics.

Information on this page was last updated on 10/30/2023.

Terry-Ann Burrell Insider Trading History at Beam Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/3/2023Sell2,454$30.31$74,380.7449,303View SEC Filing Icon  
1/26/2023Sell1,102$45.16$49,766.3231,277View SEC Filing Icon  
1/24/2023Sell14,810$45.01$666,598.1031,277View SEC Filing Icon  
1/18/2023Sell47,195$45.14$2,130,382.3031,277View SEC Filing Icon  
3/31/2022Sell1,787$59.11$105,629.5738,278View SEC Filing Icon  
6/30/2021Sell30,000$122.00$3,660,000.00View SEC Filing Icon  
6/28/2021Sell45,000$107.69$4,846,050.0069,809View SEC Filing Icon  
See Full Table

Terry-Ann Burrell Buying and Selling Activity at Beam Therapeutics

This chart shows Terry-Ann Burrell's buying and selling at Beam Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Beam Therapeutics Company Overview

Beam Therapeutics logo
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 and BEAM-102 for the treatment of sickle cell disease beta thalassemia; BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease; and the Institute of Molecular and Clinical Ophthalmology Basel for treatment of impaired vision and blindness. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
Read More

Today's Range

Now: $26.40
Low: $26.29
High: $28.79

50 Day Range

MA: $23.95
Low: $17.69
High: $30.76

2 Week Range

Now: $26.40
Low: $16.95
High: $51.60


1,780,125 shs

Average Volume

1,444,542 shs

Market Capitalization

$2.15 billion

P/E Ratio


Dividend Yield



New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Check out this training for the full story!